MEDIA

All patients have now completed their last visit in Nanexa’s Phase I trial of NEX-22 in Type 2 diabetes

5 November, 2024
- Press Release
Download attachment

Nanexa AB today announced that all patients have now completed the company's Phase I study for NEX-22 in type 2 diabetes. The study evaluates a long-acting depot formulation of the GLP-1 analog liraglutide with Nanexa's patented PharmaShell® system.

All patients’ visits to the study clinic have now been completed according to plan. The analysis of the last blood samples taken is now the only thing that remains, as part of the evaluation of the pharmacokinetic profile of the treatment. The target is to have a one-month depot formulation to simplify and improve patients’ adherence to prescribed treatment, and in the end achieve a better outcome.

We are very pleased to have finished this important study according to plan and look forward to presenting the results, says David Westberg, CEO of Nanexa.

For additional information, please contact:

David Westberg – CEO, Nanexa AB (publ) 
Phone: +46 70 942 83 03
Email: david.westberg@nanexa.se
www.nanexa.com

The company’s Certified Adviser is Carnegie Investment Bank AB (publ).

About Nanexa AB (publ)

Nanexa is a pharmaceutical company developing injectable drug products based on the proprietary and innovative drug delivery system PharmaShell® – the high drug load delivery system enabling the next generation long-acting injectables through atomic layer precision. Nanexa develops its own products and also has collaboration agreements with several pharma companies, among others Novo Nordisk and AstraZeneca.

Nanexa’s share is listed on Nasdaq First North Growth Market in Stockholm (NANEXA).

Attachments

All patients have now completed their last visit in Nanexa’s Phase I trial of NEX-22 in Type 2 diabetes